Co-delivery of Ruthenium Polypyridyl Complex (RPC) and Cisplatin for the Treatment of Cancer
-
1
Putra Malaysia University, Malaysia
Background
Ruthenium Polypyridyl Complex (RPC), which is a metal complex has been investigated as a potential anti-cancer agent for the treatment of various cancer. However, information pertaining to the effects of combining RPC with existing chemotherapeutic drugs remain scarce. This study aimed to investigate the possible synergistic cytotoxic effects of using RPC in combination with cisplatin on different cancer cell lines.
Methods
A549, MCF7, Hela and T24 cells were treated with different concentrations of RPC or cisplatin alone, as well as different combinations of these two agents at a fixed ratio 1:1 over the course of 72 hr to assess their individual and combination effects. Cell viability was analysed using MTT assay. The combination index (CI) was calculated based on the Chou Talalay Method.
Results
Single-agent treatment at 72 hr with RPC or cisplatin led to dose-dependent decreases in the viability of the A549, MCF7, Hela and T24 cells at 72 hr. Furthermore, increasing the concentrations of the combinations up to four folds of half maximal inhibitory concentration (IC50) statistically decrease the cell survival rates of A549 and MCF7 cells thus, displayed synergistic effects.
Conclusion
Treatment of MCF7 and A549 cells with a combination of RPC and cisplatin showed a synergistic effect and thus are promising as an alternative for cancer treatment.
Acknowledgements
This study was supported by FRGS/1/2017/STG01/UPM/02/6(01-01-17-1913FR) entitled In-Vitro Evaluation Of Novel Mesoporous Silica Nanovehicles For The Delivery Of Ruthenium(II) Anticancer Drug.
Keywords:
Ruthenium polypridyl complex,
anticancer,
Chou Talalay Method,
Cisplatin,
Synergistic cytotoxicity
Conference:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019.
Presentation Type:
Poster Presentation
Topic:
Cancer CaRE
Citation:
Ahmad
H,
Yusoh
N,
Harun
S and
Lin
CS
(2019). Co-delivery of Ruthenium Polypyridyl Complex (RPC) and Cisplatin for the Treatment of Cancer.
Front. Pharmacol.
Conference Abstract:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”.
doi: 10.3389/conf.fphar.2019.63.00042
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
30 Jan 2019;
Published Online:
27 Sep 2019.
*
Correspondence:
Dr. Haslina Ahmad, Putra Malaysia University, Seri Kembangan, Malaysia, haslina_ahmad@upm.edu.my